ALLR
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. (ALLR) is currently in a range/mixed trend, trading below both the 50-day and 200-day moving averages. RSI is at 40.0, with 1/3 trend checks passing.
ALLR with MA50 and MA200
Key levels & signals
Allarity Therapeutics, Inc. (ALLR) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $1.18, and 1 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 18.2% and below the 200-day moving average by 6.3%.
ALLR currently has an RSI reading of 40.0, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
This page is designed to help you quickly understand what the ALLR chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Learn the indicators behind this page
More stock opportunities
Common questions about ALLR
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.